Summary
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Operator Greetings, and welcome to the MDxHealth Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded.
MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024
MDxHealth (NASDAQ: MDXH ) just reported results for the second quarter of 2024. MDxHealth reported earnings per share of -42 cents.
MdxHealth SA Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 20,767 | $74,138.04 | $8,771.98 | -$65,366.06 | -88.17% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 28,046 | $64,506 | $11,913.94 | -$52,592.06 | -81.53% |
| RG Robert Glass AlphaCentric Advisors LLC | 32,951 | $117,635.07 | $14,435.83 | -$103,199.24 | -87.73% |
| TK Taro Kuriyama Axq Capita LLP | 15,954 | $36,694 | $6,718.23 | -$29,975.77 | -81.69% |
| IC Irene Chou Panoramic Capital LLC | 238,668 | $1.02M | $103,080.71 | -$916,364.13 | -89.89% |
MdxHealth SA Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 512.41 | $278.24 | $224.95 | -$53.29 | -19.15% |
 Jason Bednar Piper Sandler | -14,038.63 | $30,224.76 | $5,934.13 | $24,290.63 | 80.37% |
MdxHealth SA (MDXH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MdxHealth SA ever had a stock split?
MdxHealth SA Profile
| Professional Services Industry | Industrials Sector | Michael K. McGarrity CEO | NASDAQ (CM) Exchange | 58286E102 CUSIP |
| BE Country | 312 Employees | - Last Dividend | 14 Nov 2023 Last Split | 4 Nov 2021 IPO Date |
Overview
MDxHealth SA is a commercial-stage precision diagnostics company that specializes in innovative urologic solutions. With a firm presence in the United States, Europe, and various international markets, the company leverages cutting-edge technology to advance the diagnosis of urological conditions, primarily focusing on prostate cancer. MDxHealth’s journey began as OncoMethylome Sciences SA, after which it underwent a rebranding to its current name in October 2010, signaling a focused strategic direction. Since its incorporation in 2003, headquartered in Herstal, Belgium, MDxHealth has dedicated itself to the development and commercialization of genomic testing solutions designed to improve patient outcomes while minimizing unnecessary medical procedures.
Products and Services
- SelectMDx
This non-invasive urine test represents a significant leap in the early detection of prostate cancer. SelectMDx leverages molecular diagnostics to analyze genetic markers, offering clinicians a powerful tool to assess the risk of prostate cancer without the need for invasive testing procedures. By identifying patients at higher risk, SelectMDx facilitates a tailored clinical approach, ensuring that invasive interventions, such as biopsies, are reserved for those most likely to benefit from them.
- ConfirmMDx
An epigenetic test that addresses the limitations of traditional biopsy procedures. ConfirmMDx is designed to detect the epigenetic changes associated with prostate cancer, offering a level of diagnostic insight beyond what typical histological analysis can provide. This test helps in reducing the risk of false-negative biopsy results, thereby helping clinicians to make more informed decisions regarding the necessity for repeat biopsies. By providing a molecular understanding of the prostate tissue, ConfirmMDx plays a crucial role in distinguishing between patients who have a higher likelihood of harboring clinically significant prostate cancer and those who do not.
